FDA Approves Omalizumab to Reduce Food-Based Allergic Reactions in Adult and Pediatric Patients
Pharmacy Times
FEBRUARY 16, 2024
This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.
Let's personalize your content